News

Acadia Pharma is expected to recruit approximately 200 patients at clinical sites located in North America. Patients in the trial will be randomised on a one-to-one basis to

Bio-Path stated that the Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The pharmacokinetics of L-Grb-2 in

Versartis said that VRS-317, a once monthly form of human growth hormone for the treatment of children and adults with growth hormone deficiency. Earlier, SynCo Bio Partners (SynCo)

Most recently, Dr Miller has served as a chief medical officer of PTC Therapeutics and led the strategic design and implementation of development activities for the company’s clinical-stage

Shionogi said that Cuvposa is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including salivary glands. Cuvposa indirectly reduces the rate of salivation

Devax claimed that its Axxess System technology is a proprietary self-expanding Nitinol stent specifically designed for the treatment of coronary and vascular bifurcation lesions. The conical shape of

Abraxane is a solvent-free chemotherapy treatment option for metastatic breast cancer which was developed using Abraxis BioScience’s proprietary nab technology platform. Abraxis BioScience said that it has granted

Abbott said that Simcor is a prescription medication used along with diet in people who cannot control their cholesterol levels by diet and exercise alone. Simcor is approved

As per the terms of the extended agreement, Regeneron Pharma is expected to receive $165m upfront and another $130m in June 2018 from Astellas, unless it terminates the